Your browser doesn't support javascript.
loading
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Pfister, David G; Haddad, Robert I; Worden, Francis P; Weiss, Jared; Mehra, Ranee; Chow, Laura Q M; Liu, Stephen V; Kang, Hyunseok; Saba, Nabil F; Wirth, Lori J; Sukari, Ammar; Massarelli, Erminia; Ayers, Mark; Albright, Andrew; Webber, Andrea L; Mogg, Robin; Lunceford, Jared; Huang, Lingkang; Cristescu, Razvan; Cheng, Jonathan; Seiwert, Tanguy Y; Bauml, Joshua M.
Afiliación
  • Pfister DG; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Worden FP; Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan, USA.
  • Weiss J; Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
  • Mehra R; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Chow LQM; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Liu SV; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
  • Kang H; The University of Texas at Austin, Dell Medical School, Texas, Austin, USA.
  • Saba NF; Department of Medicine, Georgetown University Medical Center, Washington, DC, USA.
  • Wirth LJ; Department of Medical Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Sukari A; University of California, San Francisco, California, USA.
  • Massarelli E; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Ayers M; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Albright A; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
  • Webber AL; Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mogg R; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Lunceford J; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Huang L; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Cristescu R; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Cheng J; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Seiwert TY; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Bauml JM; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
Cancer Med ; 12(6): 6603-6614, 2023 03.
Article en En | MEDLINE | ID: mdl-36479637
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Antineoplásicos Inmunológicos / Neoplasias de Cabeza y Cuello Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Antineoplásicos Inmunológicos / Neoplasias de Cabeza y Cuello Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos